ReviewMaterials today. Bio2026
Revisiting the potential of upconversion nanoparticles in biomedical applications: Advances and emerging perspectives.
Review in Materials today. Bio, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Advances and Prospects of Chiral Plasmonic Nanomaterials in Emerging Applications.Nanomaterials (Basel, Switzerland) · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Upconversion nanoparticles (UCNPs) have evolved from niche photophysical systems into multifunctional platforms with growing relevance in biomedicine. Their ability to convert near-infrared (NIR) excitation into higher-energy emission enables deep tissue interrogation with minimal background and high photostability, offering clear advantages over conventional probes. This review revisits the field from a design-oriented perspective, reflecting how recent advances in synthesis, photophysical understanding, and nanoengineering have reshaped the relationship between UCNP structure and biomedical performance. Combining properties and applications highlight how rational control over architecture and interfaces governs functionality in complex biological environments. This evolving framework is discussed across major application domains, alongside emerging directions that extend UCNPs beyond passive imaging toward active and programmable systems. Despite substantial progress, key challenges persist in achieving high brightness under safe excitation, ensuring predictable biological behavior, enabling safe clearance, and improving reproducibility. Addressing these limitations through integrated material and system-level design will be critical for translating UCNPs into reliable biomedical technologies.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.